Navigation Links
Investigational drug may increase survival for some patients with advanced melanoma
Date:3/4/2014

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.

Patients who showed responses to the drug, nivolumab (anti-PD-1; BMS-936558; MDX-1106; ONO-4538), survived for an average 16.8 months following initiation of treatment. Overall, 62 percent of patients (66 of 107) were alive one year following treatment initiation, and 43 percent (46 of 107) were alive two years later. Average survival among 33 patients (31 percent) whose tumors shrank significantly was two years. The drug is now being tested in three larger, phase III trials in melanoma, which generally compare a new therapy with a standard one currently in use.

Results of the study are published online March 3 in the Journal of Clinical Oncology.

"The results seen here are remarkable for these patients with treatment-resistant, advanced metastatic melanoma, who had limited life expectancies when they joined the trial," says study lead-author Suzanne Topalian, M.D., professor of surgery and oncology, and director of the melanoma program at Johns Hopkins.

The immune-based therapy aims not to kill cancer cells directly, but to block a pathway that shields tumor cells from immune system components that are potentially able and poised to fight cancer. The pathway includes two proteins called programmed death-1 (PD-1), expressed on the surface of immune cells, and programmed death ligand-1 (PD-L1), expressed on cancer cells. When PD-1 and PD-L1 join together, they form a biochemical shield protecting tumor cells from being destroyed by the immune system. Another protein involved in the pathway, that is expressed by some tumors and by cells in the immune system, is programmed death ligand𔃀 (PD-L2), which was discovered by Johns Hopkins investigators in 2001.

One hundred seven people with advanced melanoma were given the medication, which is administered intravenously in an outpatient clinic every two weeks. Results suggest that some patients can safely remain on the treatment for up to two years. Participants received doses of 0.1, 0.3, 1, 3, or 10 mg/kg in 12 or fewer eight-week cycles of treatment. Investigators observed responses at all doses, though the highest response rate was in seven of 17 (41 percent) patients receiving 3 mg/kg, the dose now being tested in phase III trials. Participants given that amount survived an average 20.3 months following treatment initiation.

Drug-related adverse events occurred in 84 percent of patients; 22 percent had serious side effects. Among the most common serious side effects were lymphopenia (low levels of infection-fighting white blood cells circulating in the blood); diarrhea; fatigue; and endocrine disorders. Each affected 1-3 percent of participants. There were no drug-related deaths in patients with melanoma receiving nivolumab.

Several companies also are investigating anti-PD1 agents or anti-PD-L1 agents in the treatment of cancers, including melanoma.

Ultimately, investigators envision boosting the effectiveness of the therapy by combining it with other anticancer agents, including cancer vaccines, other immunotherapies, or drugs that block enzymes called kinases, the researchers say.


'/>"/>
Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine
Source:Eurekalert

Related medicine news :

1. Investigational drug effective in treating iron deficiency in kidney disease patients on dialysis
2. Investigational Drug Effective in Treating Iron Deficiency in Chronic Kidney Disease Patients on Dialysis: Study
3. NIH launches trial of investigational genital herpes vaccine
4. Investigational PARP inhibitor promising in BRCA-related cancers
5. Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
6. Investigational malaria vaccine found safe and protective
7. Method patent issued for investigational new class of pain medication
8. Investigational agent targets gene signaling pathways to improve response for patients with CLL
9. Despite recession, childrens health spending increased between 2009-2012, says new report
10. Death of partner associated with increased risk of heart attack, stroke
11. Frequent school moves can increase the risk of psychotic symptoms in early adolescence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
Breaking Medicine Technology: